What Is Claimed Is:

- 1. A method for treating irritable bowel syndrome in a subject in need of such treatment, comprising administering to said subject an amount of an excitatory opioid receptor antagonist effective to treat irritable bowel syndrome in said subject.
- 2. The method according to Claim 1, wherein said amount of the excitatory opioid receptor antagonist is effective to block at least one of hypersensitivity and hyperexcitability of visceral sensory and visceral motor neurons associated with irritable bowel syndrome.
- 3. The method according to Claim 1, wherein said amount of the excitatory opioid receptor antagonist is effective to treat abdominal pain and at least one of abnormal consistency and abnormal frequency of stools in said subject.
- 4. The method according to Claim 1, wherein said excitatory opioid receptor antagonist is a member selected from the group consisting of naltrexone, nalmefene, diprenorphine, naloxone, etorphine, dihydroetorphine, biphalin, and similarly acting opioid alkaloids or peptides.
- 5. The method according to Claim 1, wherein said excitatory opioid receptor antagonist is naltrexone.
- 6. The method according to Claim 5, wherein said naltrexone is administered at a dose effective to relieve abdominal pain associated with IBS and wherein said dose is further ineffective to induce dysphoria.

- 7. The method according to Claim 5, wherein said naltrexone is administered at a dose between about 0.1 mg/day and about 5 mg/day.
- 8. The method according to Claim 5, wherein said naltrexone is administered at a dose between about 0.3 mg/day and about 3 mg/day.
- 9. The method according to Claim 5, wherein said naltrexone is administered at a dose between about $2 \mu g/kg$ body weight/day and about 70 $\mu g/kg$ body weight/day.
- 10. The method according to Claim 5, wherein said naltrexone is administered at a dose between about 4 μ g/kg body weight/day and about 45 μ g/kg body weight/day.
- 11. The method according to Claim 1, wherein said excitatory opioid receptor antagonist is nalmefene.
- 12. The method according to Claim 11, wherein said nalmefene is administered at a dose effective to relieve abdominal pain associated with IBS and wherein said dose is further ineffective to induce dysphoria.
- 13. The method according to Claim 11, wherein said nalmefene is administered at a dose between about 0.01 mg/day and about 1 mg/day.
- 14. The method according to Claim 1, wherein said excitatory opioid receptor antagonist is administered in one or more forms selected from the group consisting of orally, parenterally, transdermally, or by suppository.

- 15. The method according to Claim 1, wherein said excitatory opioid receptor antagonist is administered orally.
- 16. A pharmaceutical composition for treating irritable bowel syndrome in a subject in need of such treatment, comprising an amount of an excitatory opioid receptor antagonist effective to treat irritable bowel syndrome in said patient.
- 17. The pharmaceutical composition according to Claim 16, wherein said amount of the excitatory opioid receptor antagonist is effective to block at least one of hypersensitivity and hyperexcitability of visceral sensory and visceral motor neurons associated with irritable bowel syndrome.
- 18. The pharmaceutical composition according to Claim 16, wherein said amount of the excitatory opioid receptor antagonist is effective to treat abdominal pain and at least one of abnormal consistency and abnormal frequency of stools in said subject, and a pharmaceutically acceptable carrier.
- 19. The pharmaceutical composition according to Claim 16, wherein said excitatory opioid receptor antagonist is a member selected from the group consisting of naltrexone, nalmefene, diprenorphine, naloxone, etorphine, dihydroetorphine, biphalin, and similarly acting opioid alkaloids or peptides.
- 20. The pharmaceutical composition according to Claim 16, wherein said excitatory opioid receptor antagonist is naltrexone.
- 21. The pharmaceutical composition according to Claim 20, wherein said naltrexone is present at a dose effective to relieve abdominal pain

associated with IBS and wherein said dose is further ineffective to induce dysphoria.

- $22.\,\,$ The pharmaceutical composition according to Claim 20, wherein said naltrexone is present at a dose between about 0.1 mg and about 5 mg.
- 23. The pharmaceutical composition according to Claim 20, wherein said naltrexone is present at a dose between about 0.3 mg and about 3 mg.
- 24. The pharmaceutical composition according to Claim 16, wherein said excitatory opioid receptor antagonist is nalmefene.
- 25. The pharmaceutical composition according to Claim 24, wherein said nalmefene is present at a dose effective to relieve abdominal pain associated with IBS and wherein said dose is further ineffective to induce dysphoria.
- 26. The pharmaceutical composition according to Claim 24, wherein said nalmefene is present at a dose between about 0.01 mg and about 1 mg.
- 27. The pharmaceutical composition according to Claim 16, wherein said pharmaceutical composition is in a form effective for administration to said patient by any member from the group consisting of orally, parenterally, transdermally, or by suppository.

28. The pharmaceutical composition according to Claim 16, wherein said excitatory opioid receptor is in a form effective to be administered orally.